Francisco Partners to Sell Medication Management Company Aesynt to Omnicell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Lower Revenues and Guidance on Omnicell (OMCL) Raises Concerns; Cowen Cuts Price Target to $29
October 30, 2015 8:24 AM EDTCowen maintained a Market Perform rating on Omnicell (NASDAQ: OMCL), and cut the price target to $29.00 (from $37.00), following the company's 3Q earnings results. OMCL reported 3Q adjusted EPS of $0.36, in-line with consensus expectations. Revenues slightly missed this quarter coming in at $125.2M, up 11.3%... More
